 | • レポートコード：B-MOR-05145 • 出版社/出版日：Mordor Intelligence / 2018年4月 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、クリティカルケア（救命救急）診断の世界市場について調べ、クリティカルケア（救命救急）診断の世界規模、市場動向、市場環境、検査の種類別分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・クリティカルケア（救命救急）診断の世界市場インサイト ・クリティカルケア（救命救急）診断の世界市場環境 ・クリティカルケア（救命救急）診断の世界市場動向 ・クリティカルケア（救命救急）診断の世界市場規模 ・クリティカルケア（救命救急）診断の世界市場規模：検査の種類別 ・クリティカルケア（救命救急）診断の世界市場規模：エンドユーザー別 ・クリティカルケア（救命救急）診断の世界市場：地域別市場規模・分析 ・クリティカルケア（救命救急）診断の北米市場規模・予測 ・クリティカルケア（救命救急）診断のアメリカ市場規模・予測 ・クリティカルケア（救命救急）診断のヨーロッパ市場規模・予測 ・クリティカルケア（救命救急）診断のアジア市場規模・予測 ・クリティカルケア（救命救急）診断の日本市場規模・予測 ・クリティカルケア（救命救急）診断の中国市場規模・予測 ・クリティカルケア（救命救急）診断のインド市場規模・予測 ・クリティカルケア（救命救急）診断の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global critical care diagnostics market is expected to register a CAGR of about 6.0% during the forecast period of 2018-2023. Critical care diagnostics deal with the specialized care and diagnosis of life-threatening diseases in patients. It is primarily driven by the increased number of physicians and patients’ demanding early disease diagnosis. As per the study scope of geographical regions, the well-established healthcare infrastructure with the high adoption rate of new technologies and increasing research and development activities provides North America an edge to sustain its high share over other regions to dominate the market.
Increasing Prevalence of Chronic Diseases and Lifestyle-related Disorders
The increasing global prevalence of chronic and lifestyle-related disorders is one of the primary factors which is propelling the critical care diagnostics market. The chronic diseases majorly include cardiovascular diseases, cancer, stroke, infectious diseases, lung disorders, diabetes, chronic kidney diseases, and liver diseases. In case of diabetes, a significant percentage of intensive care units (ICUs) admissions include patients with unknown diabetes cases showing a high percentage of hyperglycemia, insulin infusion, and blood glucose. In developed regions such as North America, the prevalence of chronic obstructive pulmonary disease (COPD) is high, followed by asthma, which require frequent critical care diagnosis or hospitalizations. Similarly, a wide range of chronic diseases need critical care, particularly in the case of elderly patients.
Other factors driving this market are the rising awareness among people for early diagnosis and treatment, rise in the use of data management and connectivity through interoperability to electronic health record (EHR), and rising adoption of telehealth services and remote communications.
High Cost of Molecular Diagnostics Tools
The high costs related to molecular diagnostics tools and treatment restricts the growth of the critical care diagnostics market. The hospitals and other healthcare facilities are spending a high percentage of the amount for the molecular tests and tools maintenance including the associated research laboratories. Moreover, the development and clinical validation of molecular diagnostic clinical tests require high level of regulations as a drug development which limits the use of molecular diagnostics despite its potential use in critical care and precision medicine.
Another factor impeding this market is the lack of skilled professionals in handling the critical care diagnostics in hospital settings.
United States to Dominate the Market
The United States is one of the primary markets for critical care diagnostics, and is expected to sustain its dominance over the forecast period. According to the Society of Critical Care Medicine, United States, an estimated six million patients are admitted annually in ICUs for invasive monitoring which includes 20% of acute care admissions and 58% of emergency departments, all needing frequent high technological support. The rise in the awareness among people for early diagnosis adds to the rise in demand for critical care diagnostics market.
Key Developments in the Market
• April 2018 – Beckman Coulter Diagnostics announced commercialization of its access sensitive estradiol in the United States for detecting estradiol levels in women, children, and men.
• January 2018 – GE Healthcare entered into the strategic, long-term partnership with Roche to jointly develop digital clinical decision support solutions for cancer and critical care patients.
Major players: ABBOTT, BAYER AG, BECTON, DICKINSON & COMPANY, BIOMÉRIEUX SA, BIO-RAD LABORATORIES, INC., CHEMBIO DIAGNOSTIC SYSTEMS, INC., DANAHER, F. HOFFMANN-LA ROCHE, SIEMENS HEALTHINEERS, AND SYSMEX CORPORATION, amongst others.
Reasons to Purchase the Report
• Current and future of the global critical care diagnostics market outlook in the developed and emerging markets.
• Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
• The segment that is expected to dominate the market.
• Regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3-month analyst support, along with the Market Estimate sheet (in Excel).
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry
6. Market Dynamics
6.1 Drivers
6.1.1 Rise in the Prevalence of Chronic Diseases and Lifestyle-related Disorders
6.1.2 Increase in Data Management and Connectivity through Interoperability to Electronic Health Record (EHR)
6.1.3 Rising Demand for Early Diagnosis and Treatment
6.1.4 Rising Adoption of Telehealth Services and Remote Communications
6.2 Restraints
6.2.1 High Cost of Molecular Diagnostics Tools
6.2.2 Lack of Skilled Professionals
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Test Type
7.1.1 Flow Cytometry
7.1.2 Hematology Tests
7.1.3 Microbial and Infectious Test
7.1.4 Coagulation Tests
7.1.5 Blood Glucose Tests
7.1.6 Others
7.2 By End User
7.2.1 Operating Rooms
7.2.2 Emergency Rooms
7.2.3 Intensive Care Units
7.2.4 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.1.4 Rest of North America
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of MEA
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott
9.2 Bayer AG
9.3 Becton, Dickinson & Company
9.4 bioMérieux SA
9.5 Bio-Rad Laboratories, Inc.
9.6 Chembio Diagnostic Systems, Inc.
9.7 Danaher
9.8 F. Hoffmann-La Roche
9.9 Siemens Healthineers
9.10 Sysmex Corporation
*List not Exhaustive
10. Future of the Market
11. Disclaimer